L

Lord Patel (CB)

Speaking in the House of Lords on 12 October 2026

Debate

Weight-loss Drugs

Contribution

My Lords, these drugs are relatively new and pretty powerful as GLP-1 and GLP-2 agonists. The important issue is safety: through NHS prescribing and MHRA reporting, we collect data on medium-term and long-term side-effects, but we do not do so through private sector prescribing. It is important that this data is collected, so would the Minister suggest that the MHRA devise a system so that private practice providers of these drugs can report medium-term and long-term side-effects?

More from Lord Patel (CB)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.